DexCom Enterprise Value Over E B I T D A from 2010 to 2024

DXCM Stock  USD 134.30  0.44  0.33%   
DexCom Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to grow to 57.19 this year. During the period from 2010 to 2024, DexCom Enterprise Value Over EBITDA quarterly data regression pattern had range of 379 and standard deviation of  111.45. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
54.46322679
Current Value
57.19
Quarterly Volatility
111.453274
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many exotic indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0206 or PTB Ratio of 24.31. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
  
This module can also supplement DexCom's financial leverage analysis and stock options assessment as well as various DexCom Technical models . Check out the analysis of DexCom Correlation against competitors.

Latest DexCom's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of DexCom Inc over the last few years. It is DexCom's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

DexCom Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(8.88)
Coefficient Of Variation(1,256)
Mean Deviation92.09
Median(14.82)
Standard Deviation111.45
Sample Variance12,422
Range379
R-Value0.57
Mean Square Error9,017
R-Squared0.33
Significance0.03
Slope14.23
Total Sum of Squares173,906

DexCom Enterprise Value Over E B I T D A History

2024 57.19
2023 54.46
2022 109.23
2021 190.0
2020 93.87
2019 125.4
2018 -100.57

About DexCom Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include DexCom income statement, its balance sheet, and the statement of cash flows. DexCom investors use historical funamental indicators, such as DexCom's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although DexCom investors may use each financial statement separately, they are all related. The changes in DexCom's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DexCom's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on DexCom Financial Statements. Understanding these patterns can help to make the right decision on long term investment in DexCom. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 54.46  57.19 

DexCom Investors Sentiment

The influence of DexCom's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in DexCom. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to DexCom's public news can be used to forecast risks associated with an investment in DexCom. The trend in average sentiment can be used to explain how an investor holding DexCom can time the market purely based on public headlines and social activities around DexCom Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
DexCom's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for DexCom's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average DexCom's news discussions. The higher the estimated score, the more favorable is the investor's outlook on DexCom.

DexCom Implied Volatility

    
  50.38  
DexCom's implied volatility exposes the market's sentiment of DexCom Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if DexCom's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that DexCom stock will not fluctuate a lot when DexCom's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards DexCom in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, DexCom's short interest history, or implied volatility extrapolated from DexCom options trading.

Pair Trading with DexCom

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.

Moving against DexCom Stock

  0.66TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.64IVP Inspire VeterinaryPairCorr
  0.59EMBC Embecta Corp Financial Report 10th of May 2024 PairCorr
  0.54AHG Akso Health GroupPairCorr
  0.47DYNT Dynatronics Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out the analysis of DexCom Correlation against competitors.
Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.81
Earnings Share
1.3
Revenue Per Share
9.384
Quarterly Revenue Growth
0.269
Return On Assets
0.0641
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.